Clinical Trial
doi: 10.1016/j.amjcard.2004.04.028.
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy
Affiliations
- PMID: 15276098
- DOI: 10.1016/j.amjcard.2004.04.028
Item in Clipboard
Clinical Trial
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy
Am J Cardiol.
.
Abstract
During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
Similar articles
-
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Ugeskr Laeger. 2001. PMID: 11601118 Clinical Trial. Danish.
-
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review.
-
Electrocardiographic abnormalities in diabetes mellitus: association between T-wave changes and nephropathy.Mt Sinai J Med. 1986 Apr;53(4):254-9. Mt Sinai J Med. 1986. PMID: 3487720 No abstract available.
-
A large frontal QRS-T angle is a strong predictor of the long-term risk of myocardial infarction and all-cause mortality in the diabetic population.J Diabetes Complications. 2017 Mar;31(3):551-555. doi: 10.1016/j.jdiacomp.2016.12.001. Epub 2016 Dec 16. J Diabetes Complications. 2017. PMID: 28065667
-
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.Int J Clin Pract. 2007 Oct;61(10):1626-33. doi: 10.1111/j.1742-1241.2007.01343.x. Int J Clin Pract. 2007. PMID: 17877649 Review.
Cited by
-
Association between the triglyceride-glucose index and silent myocardial infarction in the general population.Sci Rep. 2025 Mar 12;15(1):8571. doi: 10.1038/s41598-025-92779-y. Sci Rep. 2025. PMID: 40075094 Free PMC article.
-
Relation of glycemic status with unrecognized MI and the subsequent risk of mortality: The Jackson Heart Study.Am J Prev Cardiol. 2022 May 10;11:100348. doi: 10.1016/j.ajpc.2022.100348. eCollection 2022 Sep. Am J Prev Cardiol. 2022. PMID: 35600110 Free PMC article.
-
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.Diabetes Care. 2011 Jun;34(6):1394-6. doi: 10.2337/dc10-2398. Epub 2011 May 11. Diabetes Care. 2011. PMID: 21562320 Free PMC article. Clinical Trial.
-
Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study.Circulation. 2016 May 31;133(22):2141-8. doi: 10.1161/CIRCULATIONAHA.115.021177. Epub 2016 May 16. Circulation. 2016. PMID: 27185168 Free PMC article.
-
The unexpected silent manifestation of myocardial infarctions in ischemic heart failure patients: Insights from a case-control study.Clinics (Sao Paulo). 2024 Aug 29;79:100480. doi: 10.1016/j.clinsp.2024.100480. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 39213801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
